Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Q3 2023 Earnings Presentation
23 slides from Marinomed Biotech's earnings presentation, Nov 21, 2023
Slide 1: Investor Presentation Q3 2023
Investor Presentation Q3 2023 Andreas Grassauer, CEO, Pascal Schmidt, CFO 21st November 2023
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda • Highlights year-to-date 2023 Andreas Grassauer, CEO • Financials Q1-Q3 2023 Pascal Schmidt, CFO • Growth strategy Andreas Grassauer, CEO • Project outlook • Financial calendar, contact © Marinomed Biotech AG 3
Slide 4: Highlights year-to-date 2023
Highlights year-to-date 2023 Progress and new products EUR 7.2 m New products BD progress revenues Stable Carragelose eye drops and Successful partnering events Carragelose allergy blocker – launch & progress with business revenues planned for 2024 development © Marinomed Biotech AG 4
Slide 5: Successful partnering events
Successful partnering events Great interest in Carragelose, Marinosolv and Solv4U technology partnerships CPHI Barcelona BIO-Europe Munich Jefferies October 24-26 November 06-08 Healthcare 170+ meetings 85+ meetings Conference London November 16-18 15+ scheduled meetings © Informa Markets, a trading
Slide 6: Agenda
Agenda • Highlights year-to-date 2023 Andreas Grassauer, CEO • Financials Q1-Q3 2023 Pascal Schmidt, CFO • Growth strategy Andreas Grassauer, CEO • Project outlook • Financial calendar, contact © Marinomed Biotech AG 6
Slide 7: Stable Q3 revenues
Stable Q3 revenues Carragelose stable in Q3 with post-pandemic slow-down of customer orders Y-o-Y comparison of quarterly revenues (m€) Comments 7.1 7.2 Historical numbers • Revenues stable at €7.2m (previous year €7.1m) 2.4 3.3 2.5 • EBIT decreased from €3.8m to €4.4m due to higher 1.9 2.2 1.9 R&D
Slide 8: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) Higher revenues – increased R&D expenses Q1-Q3 Q1-Q3 1 Q1-Q3 2023 Q1-Q3 2022 €m 2023 2022 Sale of goods 6.3 6.5 Revenues 1 7.2 7.1 Cost of goods sold -4.6 -4.5 Margin 28.2% 31.6% Other income 2 0.3 0.6 Materials expenses -4.6 -4.6 •2 Primarily consisting of researc
Slide 9: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m Q3 2023 FY 2022 •1 Includes fully recognized headquarter, incl. land and building (€5.3m), therein directly R&D related* (€0.5m) Assets Intangible assets 1.6 1.8 2 Inventories €m Q3 2023 FY 2022 Property, plant and equipment 1 6.0 6.2 Goods for sale 0
Slide 10: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m Q3 2023 FY 2022 •1 Primarily related to EIB loan (€15.0m) and ERP/aws and NÖBEG real estate refinancing (€4.8m) Equity and liabilities Share capital 1.5 1.5 Majority of accrued interest payable at maturity of loans. Capital reserves 44
Slide 11: Cash reach into 2024
Cash reach into 2024 Debt and interest repayments reducing cash position, taking measures 1• Operations mainly consisting of personnel costs and R&D expenses; MDR switch temporarily also contributing 1 2• Repayments of EIB loan increasing cash burn 1 2 3• Tax receivable of €0.8m (mostly research pre
Slide 12: Agenda
Agenda • Highlights year-to-date 2023 Andreas Grassauer, CEO • Financials Q1-Q3 2023 Pascal Schmidt, CFO • Growth strategy Andreas Grassauer, CEO • Project outlook • Financial calendar, contact © Marinomed Biotech AG 12
Slide 13: Platforms & Therapeutic Areas
Platforms & Therapeutic Areas Universal blocking of viruses and allergens as well as Solubilization of poorly water-soluble compounds and moistening of mucosal tissues improving local onset of action Cough & Allergy Eye drops Budesolv Tacrosolv Solv4U cold portfolio nasal spray Dry, irritated eyes A
Slide 14: Carragelose®
Carragelose® CCA2 market volume: Protective layer against viruses and allergens – multi-use potential US$ 36 bn3 Viral respiratory diseases Carragelose Eye care • Broadly-active against numerous • Carragelose has excellent respiratory viruses moisturizing and mucoadhesive properties • Clinically val
Slide 15: Allergen-blocking properties
Allergen-blocking properties Carragelose functions as barrier against allergens in-vitro Allergen-blocking properties Effective blocking of allergens • Inhibition of allergen contact to mucosa tested in a surrogate in- 120 vitro test system 100 • Superior compared to marketed HPMC3-based product (Na
Slide 16: Pipeline
Pipeline Including late-stage projects with low risk and high upside potential © Marinomed Biotech AG 16
Slide 17: Immunology – focus on business development
Immunology – focus on business development Enable new partnerships and prepare launches Product Action item Status / next steps Continue ongoing BD efforts: clear regulatory path & timelines for Enable a near term partnership filing and marketing authorization for MAM-1004-1/Budesolv key regions Tre
Slide 18: Virology – growth strategy
Virology – growth strategy Expansion of territory, indication and product portfolio Product Action item Status / next steps Virus-blocking OTC portfolio Existing Partnerships USA (Procter & Gamble), Mexico and USA → FDA registration Brazil (M81) Mexico → Launch in early 2024 Brazil → ANVISA registra
Slide 19: Solv4U Technology Partnerships
Solv4U Technology Partnerships Increase BD activities and support ongoing partnerships Product Action item Status / next steps Work on leads generated at trade fairs A series of feasibility projects have Solv4U Increase BD activities - continue been completed - progress current Marinosolv for extern
Slide 20: Outlook
Outlook Continue strategy with focus on near-term revenues • Stable first 9 months - Carragelose revenues in the upcoming quarters impacted by post-pandemic effects Strengthen Carragelose • Drive Carragelose in the U.S., Mexico and others business • Launch Carragelose allergy and eye products in 202
Slide 21: Agenda
Agenda • Highlights year-to-date 2023 Andreas Grassauer, CEO • Financials Q1-Q3 2023 Pascal Schmidt, CFO • Growth strategy Andreas Grassauer, CEO • Project outlook • Financial calendar, contact © Marinomed Biotech AG 21
Slide 22: Financial calendar 2024 & IR contact
Financial calendar 2024 & IR contact Financial Calendar 2024 Publication of the Annual Report and 16.04.2024 Sustainability Report 2023 22.05.2024 Publication of the Results Q1 2024 20.06.2024 7th Annual General Meeting 20.08.2024 Publication of the Results H1 2024 Stephanie Kniep 21.11.2024 Publica
Slide 23: www.marinomed.com
www.marinomed.com 0) Marinomed